Kiniksa Pharmaceuticals International Plc Dossier - Source-backed chat

Kiniksa Pharmaceuticals International Plc

KNSANASDAQ

SectorHealth Care

IndustryDrug Manufacturers - Specialty & Generic

Beta (adjusted)0.40

Intrinsic Value $64.07median of 6 methods · middle span $54-$1,046based on filings through 31 Mar 2026

Market Price $75.22Price as of 1 Oct 2026

Near fair valueIntrinsic value is 15% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $5.9B

Enterprise Value $5.7B

Shares Outstanding 85.2M diluted

Moat Rating Wide

Next Earnings Date30 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Kiniksa Pharmaceuticals presents a compelling investment opportunity driven by the robust commercial execution of its flagship product, ARCALYST, which continues to deliver high double-digit year-over-year growth in the recurrent pericarditis market. The company's transition to sustained profitability, combined with a debt-free balance sheet and a strong cash position of $468.1 million, provides a highly stable financial foundation. Furthermore, Kiniksa is actively advancing its clinical pipeline, with key readouts for KPL-387 expected in the second half of 2026 and the planned initiation of a Phase 1 trial for KPL-1161. These catalysts, alongside raised full-year 2026 revenue guidance, support a highly favorable risk-reward profile.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$87.00

Mean target$98.00

High · most bullish analyst$108.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$87.00

ARCALYST sales growth slows down due to reaching a penetration plateau in the multiple-recurrence patient population or facing unexpected reimbursement hurdles from payers. Additionally, KPL-387 Phase 2 data fails to show clear clinical differentiation or monthly dosing durability, delaying the initiation of the Phase 3 trial and increasing the company's long-term R&D cash burn.

Base CaseCentral scenario

$98.00

Matches the consensus mean

ARCALYST continues its steady commercial trajectory, meeting the raised full-year 2026 net product revenue guidance of $930 million to $945 million. The company maintains annual positive cash flow and profitability. KPL-387 Phase 2 data is successfully delivered in the second half of 2026, allowing the company to initiate its Phase 3 pivotal trial by year-end, while KPL-1161 enters Phase 1 clinical development as scheduled.

Bull CaseUpside scenario

$108.00

ARCALYST adoption accelerates faster than expected, driven by successful direct-to-consumer campaigns and higher repeat prescriber rates, pushing full-year 2026 revenues past the upper bound of guidance ($945 million). Concurrently, KPL-387 Phase 2 data in the second half of 2026 demonstrates superior efficacy and a highly convenient monthly subcutaneous dosing profile, paving the way for a rapid Phase 3 trial and establishing a dominant long-term franchise in cardiovascular inflammation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial momentum with ARCALYST, delivering 56% year-over-year growth in Q1 2026 and leading to an upward revision of full-year guidance.
Robust financial health, characterized by $468.1 million in cash and short-term investments, zero debt, and a commitment to remaining cash flow positive on an annual basis.
Highly promising pipeline with KPL-387 (Phase 2/3) and KPL-1161 (Phase 1) targeting significant unmet needs in cardiovascular and autoimmune indications.

Key Investment Risks

High concentration of revenue on a single commercial asset (ARCALYST), making the company vulnerable to any commercial or regulatory setbacks with this product.
Clinical development risk associated with the upcoming Phase 2 data readout for KPL-387 and the Phase 1 initiation of KPL-1161.
Potential long-term competition from emerging therapies or biosimilars in the recurrent pericarditis and IL-1 inhibition space.

Thesis Invalidation Triggers

A significant miss in ARCALYST quarterly net product revenues below the guided trajectory.
Failure of KPL-387 Phase 2 data to meet primary efficacy endpoints or demonstrate a viable monthly dosing profile.
Unexpected regulatory or safety issues arising with ARCALYST that restrict its current label or market access.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.